Leadership Appointments Bodes Well with Strategic Focus - Report on Zogenix, Inc.

Jul 21, 2015, 09:10 ET from www.aciassociation.com

NEW YORK, July 21, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on Zogenix, Inc. (NASDAQ: ZGNX). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

Today, membership is open to readers on a complementary basis at the following URL: http://www.aciassociation.com/?c=ZGNX

Highlights from our ZGNX Report include:

  •  Appointments of Dr. Gail M. Farfel & Dr. Thierry Darcis - On July 6, 2015, Zogenix, Inc., a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced two leadership appointments with Gail M. Farfel, Ph.D., as its Executive Vice President and Chief Development Officer, while Thierry Darcis, M.D., to serve as Executive Vice President and General Manager, Europe. The Company informed that in her new role of Chief Development Officer, Dr. Farfel will lead all product development activities, including clinical development and regulatory strategy. On the other hand, Dr. Darcis will establish Zogenix's pre-commercial presence in Europe and lead commercial operations in Europe directed towards the anticipated launch of ZX008. According to CEO Dr. Stephen Farr, these appointments further advance the Company's core strategic focus on its late-stage CNS product development pipeline.
  • Dr. Farfel Brings Experience of Over Two Decades in the Area of CNS Disorders -- The Company informed that Dr. Farfel has over 20 years of experience in leading drug development projects for multiple CNS indications, including epilepsy. Prior to her new role, she served as Chief Clinical and Regulatory Officer of Marinus Pharmaceuticals, wherein she was responsible for establishing and managing clinical, medical and regulatory strategies for adult and pediatric seizure disorders, including a pediatric epileptic orphan disease. Earlier, Dr. Farfel has also served as Vice President, Therapeutic Area and Head for Neuroscience Clinical Development and Medical Affairs at Novartis Pharmaceuticals Corporation, where she managed a portfolio of products including Gilenya® for multiple sclerosis, Exelon® and the Exelon® Patch for Alzheimer's disease and Parkinson's disease.
  • Dr. Darcis's profile -- As per Zogenix Dr. Darcis holds over 20 years of pharmaceutical industry experience in global marketing, product development and operations management. He has led European operations as General Manager for two successful rare disease-focused biopharmaceutical organizations, most recently NPS  Pharmaceuticals and prior to that, Viropharma Europe. Earlier, he has also served as Vice President, Global Marketing Head and a member of the executive team at Novartis Vaccines and has also served GlaxoSmithKline Biologicals in Belgium for more than five years.

To find out how this influences our rating on Zogenix, Inc. read the full report in its entirety here: http://www.aciassociation.com/?c=ZGNX

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ACI Association, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.

RESTRICTIONS 

ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) aciassociation.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.aciassociation.com